Introduction
Neonates with congenital and acquired gastrointestinal disorders (GDs) are at high risk for parenteral nutrition-associated liver disease (PNALD). 1, 2 The mortality for most children with GDs is low, and most cases of PNALD are transient. 1 However, in a subpopulation of neonates with GDs who have intestinal failure secondary to short bowel syndrome and/or severe gastrointestinal dysmotility, PNALD is associated with an increased risk for bleeding, impaired hepatic drug metabolism, and portal hypertension followed by liver failure. 1, 2 Advanced PNALD remains the leading cause of mortality for children with GDs and is the most common diagnosis for children awaiting a combined small bowel/liver transplant. [2] [3] [4] The goal of transplant is to restore normal liver function and/or obtain enteral autonomy. However, transplants are expensive and associated with a 5-year patient and graft survival rate of 65%-75%. 5, 6 Moreover, the posttransplant course can be fraught with infections, malignancy, and graft rejection.
Preventative PNALD strategies are lacking and needed. The discontinuation of parenteral nutrition (PN) is the most effective preventative and treatment strategy for PNALD. In some cases, this may not be possible because of gestational age, critical illness, and gastrointestinal (GI) anatomy and function. The dose and composition of intravenous (IV) lipid emulsions are thought to play an important role in PNALD. [7] [8] [9] [10] [11] [12] [13] [14] [15] Soybean-based IV lipid emulsions (S-ILEs) are a source of calories and essential fatty acids. The S-ILE products approved by the Food and Drug Administration (FDA) are traditionally dosed at 3 g/kg/d and contain high doses of hepatoxic and inflammatory phytosterols and polyunsaturated ω-6 fatty acids. 13, 14 By reducing the dose of S-ILE, the liver may be exposed to decreased concentrations of these substances and, therefore, less susceptible to hepatic injury. Neonates with intestinal failure may reap the most benefit from lipid sparing. However, this group is at high risk for failure to thrive, which, in turn, is associated with poor cognitive and behavioral outcomes. 9, 16 Current literature is conflicting as to whether a reduced dose of S-ILE can prevent PNALD without compromising growth. 7, 8, 12, 17, 18 This pilot study's purpose was to demonstrate feasibility and investigate the effect of a reduced dose of S-ILE, compared with the standard dose of S-ILE, on liver function and short-term growth in neonates with GDs.
Methods

Study Outcomes
The primary outcome for this preliminary study was cholestasis (serum direct bilirubin [DB] >2 mg/dL). Secondary outcomes included weight velocity at 28 days of age, PN duration, and late-onset sepsis (positive blood culture in infants >72 hours of age and requiring at least 5 days of IV antibiotics). Tertiary outcomes included maximum serum DB, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and triglyceride concentrations; DB >1 mg/dL; number of days to reach maximum DB; and DB rate of change ([maximum serum DB -baseline DB]/number weeks to reach maximum serum DB). Cholestasis and DB >1 mg/dL were determined after the first 7 days of age and prior to hospital discharge, withdrawal, or death, whichever came first.
Patient Population
Neonates with GDs (gastroschisis, omphalocele, small bowel atresia, intestinal perforation, Hirschsprung disease, volvulus, or meconium ileus and/or peritonitis) and who were ≤5 days of age at enrollment were included in this study. Patients with an inability to provide informed consent or who had a primary liver disorder excluding PNALD, congenital intrauterine infection, metabolic disorder, or terminal illness were excluded. Informed, written consent was obtained from all parents/legal guardians. The FDA (IND 122,478) and institutional review boards at each institution approved the study.
Study Procedures and Methods
Randomization was stratified by site and blocks of 4 by using sealed opaque envelopes. Patients were randomized to either a low (~1 g/kg/d IV, LOW) or the standard dose (~3 g/kg/d IV, CON) of S-ILE (20% Intralipid; Fresenius Kabi, Uppsala, Sweden) in an unmasked fashion. According to clinical practice in the participating centers, S-ILE was initiated in the first 24-48 hours of age and advanced by 0.5-1 g/kg/d to the target dose depending on triglyceride tolerance. The intervention continued until the patient reached approximately 100 days of age, was weaned from PN, discharged from the hospital, or died, whichever came first. If PN was discontinued and restarted prior to 100 days of age, the patient was prescribed the dose to which he or she was randomized.
Patients received PN composed of dextrose and amino acids (10% Premasol; Baxter, Deerfield, IL). Goal calories and amino acid doses for term and low-birth-weight neonates were approximately 100 and 120 kcal/kg/d and 3 g/kg/d and 3-4 g/ kg/d, respectively. Goal glucose infusion rates were increased to a maximum of 12-16 mg/kg/min and adjusted at the discretion of the primary medical team based on glucose tolerance, goal calories, and growth. Enteral feeds were initiated and advanced per routine care. For CON patients receiving >50%-75% of calories from enteral nutrition (EN), the S-ILE dose could be reduced by approximately 50%. S-ILE could be held or reduced by 50% for hyperglycemia (serum glucose >200 mg/dL) or hypertriglyceridemia (serum triglyceride concentration >200 mg/dL). Once hyperglycemia or hypertriglyceridemia resolved, S-ILE was advanced to the target dose.
Study outcomes and adverse events were collected until a patient was discharged from the hospital or died. Adverse events included hyperglycemia (serum glucose >200 mg/dL for ≥3 consecutive measurements separated by 2 hours) and hypertriglyceridemia (serum triglyceride concentration >200 mg/dL for ≥2 consecutive measurements separated by 24 hours). According to routine practice, serum DB concentrations were measured at least weekly for any neonate receiving PN for >14 days and/or who developed cholestasis.
At both study institutions, a fish-based IV lipid emulsion (Omegaven; Fresenius Kabi, Bad Homberg, Germany) was available under a research protocol or compassionate use. Because of the institutions' experience with IV fish oil and published literature that demonstrates that IV fish oil can promote biochemical resolution of PNALD, patients who were considered high risk for advanced PNALD could withdrawal from the study to receive fish oil. 9, 10 The decision to withdraw was made by the parents/legal guardians along with consultation with a multidisciplinary team that included neonatology, pediatric surgery, and/or pediatric gastroenterology. At the time of withdrawal, the study intervention ceased, but data collection continued until hospital discharge. A Data Safety Monitoring Committee met on an annual basis to review safety outcomes.
Statistical Methods and Analysis
Prior to the start of the study, the incidence of cholestasis at the lead site was approximately 40%-45%. To detect a 50% reduction in the primary outcome with a type I error of 5% and power of 80%, approximately 60 patients per arm would be required. Because of a much slower than anticipated enrollment, a preliminary analysis was performed. The analysis revealed that the sample size would not yield a statistically significant difference for the primary outcome between the 2 arms and that further enrollment would be futile.
Patients who required an abdominal operation (excluding gastrostomy tubes and rectal biopsies) and received PN for >14 days were included in the final analysis. Categorical variables were examined using the Fisher exact test. For continuous variables, differences were assessed using the Student t test. Repeated measures with an autoregressive covariance structure were used to compare longitudinal data on growth, PN and EN, and laboratory values. For DB values reported as "nondetectable," a value of 0.1 mg/dL was assumed. One patient in the LOW group had abnormally high AST and ALT concentrations at the start of the study. When these values were removed from the analyses, the results were qualitatively the same (data not shown).
Statistical analyses were performed with SAS 9.3 (SAS Institute, Cary, NC). P < .05 was considered statistically significant. No adjustments were made for multiple comparisons. Nonlongitudinal data are presented as means ± SD. Longitudinal data are presented as means ± SE.
Results
Between October 2010 and February 2014, a total of 41 patients were enrolled and randomized. Five patients were excluded because they received ≤14 days of PN and/or did not have an abdominal operation. The final analysis included 36 patients (LOW = 20, CON = 16) (Figure 1 ). Baseline characteristics and laboratory values were comparable between the 2 groups with 75% of patients in each group being diagnosed with gastroschisis at birth ( Table 1) . Thirty percent of the LOW group and 38% of the CON developed the primary outcome of cholestasis (P = . 7) . No difference was demonstrated in any of the secondary outcomes (Table 2) . Maximum serum DB (1.5 ± 1.4 vs 1.9 ± 1.8 mg/dL, P = .5) and time to reach this milestone (25 ± 13 vs 27 ± 14 days, P = .6) were comparable for the LOW and CON groups, respectively. The rate of change for DB, from baseline to the maximum value recorded (0.3 ± 0.08 vs 0.5 ± 0.09 mg/dL/wk, P = .2), and other liver function tests were not significantly different when the LOW group was compared with the CON group. However, the DB rates of change for the first 8 weeks (0.07 ± 0.04 vs 0.3 ± 0.09 mg/dL/ wk, P = .01) and entire study period (0.008 ± 0.03 vs 0.2 ± 0.07 mg/dL/wk, P = .02) were significantly lower in the LOW group vs the CON group (Table 3 and Figure 2A) .
Growth velocity over the first month of age was similar in the LOW group compared with the CON group (18 ± 8 vs 24 ± 16 g/d, P = .3) ( Table 2) . Weight change over time and discharge weight, length, and head circumference did not differ between the 2 groups (Tables 2 and 4 ). Glucose delivery rate (P = .6), parenteral amino acids (P = .3), parenteral calories (P = .4), and enteral calories (P = .8) over time were similar between the 2 groups ( Table 4) . As expected, at the start of the first study week, the LOW group received slightly less total parenteral calories (88 ± 2 vs 100 ± 5 kcal/kg/d, P = .08) and significantly less S-ILE (1 ± 0.01 vs 2.9 ± 0. g/kg/d, P < .001) than the CON group. For each week on the study, the S-ILE dose decreased by 0.01 ± 0.005 mg/kg/d in the LOW group and Table 4) . None of the patients were receiving EN at enrollment, and EN was initiated at 18 ± 9 and 17 ± 8 days of age in the LOW and CON groups, respectively (P = .7). The incidence of cholestasis at the 2 study sites was not different when the LOW group was compared with the CON group (P = 1 at each site). For patients who received PN for >28 days, the incidence of cholestasis was 30% for the LOW group and 40% for the CON group (P = .7). Moreover, the maximum DB was not statistically significant when the LOW group was compared with the CON group (1.7 ± 1.4 vs 2.5 ± 2 mg/dL, P = .5) ( Figure 2B ).
Adverse events occurred infrequently in this study with comparable incidences of hyperglycemia (10% vs 0%, P = .5) and hypertriglyceridemia (0% vs 6%, P = .4) in the LOW and CON groups, respectively. One CON patient was withdrawn from the study to receive IV fish oil at 81 days of age. The DB prior to withdrawal was 3.5 mg/dL. The patient was discharged home with PN. There were no deaths in the study.
Discussion
In this pilot study, a low dose (~1 g/kg/d) compared with a higher dose of S-ILE (~3 g/kg/d) was not associated with a change in cholestasis or short-term growth (Tables 2 and 4 ).
However, serum DB rose at a slower rate over the first 8 weight weeks and the entire study period in the LOW group compared with the CON group (Table 3) . These results are in contrast to a retrospective study by Sanchez et al. 18 In this study, a 50% reduction in cholestasis was observed in surgical neonates who received 1 g/kg/d S-ILE in comparison to a historical cohort. However, it is unclear if these results are due to change in S-ILE dose or clinical practice.
Currently in the United States, only 1 lipid emulsion (20% Intralipid; Fresenius Kabi) is FDA approved. Access to alternative lipid emulsions, such as fish oil or mixed lipid emulsions, is restricted to research and compassionate use protocols. 9, 10, 19, 20 Because PNALD preventative and therapeutic options are limited, many clinicians have adopted S-ILE dose reduction.
12,17,18,21,22 Only 2 other randomized controlled studies have investigated the safety and efficacy of low-dose S-ILE in the neonatal population for PNALD prevention. 7, 8 In a study by Rollins et al, 8 30 neonates with GDs who were predicted to require >50% of their calories from PN were randomized to 1 or 3 g/kg/d S-ILE for no longer than 8 weeks. In comparison to the neonates who received the standard dose, neonates who received a reduced dose of S-ILE had a smaller median change in conjugated bilirubin (0 vs 1.3 mg/dL, P = .04) and total bile acids (2-vs 13-fold, P = .02). However, in contrast to our study, when the reduced group was compared with the standard Results are presented as a mean ± SD or number (%). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CON, control dose; DB, direct bilirubin; LOW, low dose.
group, the median rate of change for conjugated bilirubin was not different (0.02 vs 0.15 mg/dL/wk, P = .1). It remains unknown if changes in bile acids would be statistically significant in our study. In a randomized controlled trial by Levit et al 7 of 136 neonates with a gestational age of ≤29 weeks, there was no difference in cholestasis, liver function tests, or growth when the S-ILE restricted group was compared with the control group. DB rate of change was not investigated in their study. In comparison to our study, the negative findings they demonstrated may be the result of a lower PNALD incidence in low-birth-weight neonates (~10% vs 35%), a shorter PN duration (~19 vs 40 days), the use of 2 different S-ILEs, and/ or a higher glucose delivery rate in the low-dose group in comparison to the control group. To compensate for reduced lipid calories, a higher parenteral glucose delivery rate may be required when EN is limited. It remains unclear if a high glucose delivery rate may counteract the possible hepatoprotective effect of low-dose S-ILE. 23 S-ILE doses <1 g/kg/d should be used with caution considering the potential negative impact on growth and risk of an essential fatty acid deficiency and hepatic steatosis, particularly in Results are presented as a mean ± SD or number (%). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CON, control dose; DB, direct bilirubin; LOW, low dose; PN, parenteral nutrition. Results are presented as a mean ± SE. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CON, control dose; DB, direct bilirubin; GGT, γ-glutamyl transferase; LOW, low dose.
low-birth-weight neonates who have limited adipose stores and/ or neonates with minimal or no enteral intake. 8, 12, 24 IV lipid emulsions provide calories and essential fatty acids, which play a vital role in organogenesis. In the study published by Rollins et al, 8 neonates who received a reduced dose of S-ILE had decreased weight z scores in comparison to controls. Long-term growth and neurodevelopment follow-up for neonates who have received low-dose S-ILE is lacking and needed before this strategy can be widely adopted as part of clinical practice. 25 While our study did not monitor for an essential fatty acid deficiency, traditionally defined as a triene/tetrane ratio ≥0.2, this would be unlikely to occur with a dose of 1 g/kg/d S-ILE. 8 In a study of neonates with cholestasis who received 1 g/kg S-ILE twice a week, none of the patients developed a triene/tetrane ratio ≥0.2. In fact, the initial median (range) triene/tetrane ratio in the lipid-restricted group was 0.069 (0.017-0.136). After 1 month of lipid restriction, the ratio decreased to 0.025 (0.014-0.052). However, neonates may still be at risk for a deficiency in a specific fatty acid. 12 The increased use of and research on alternative lipid emulsions for PNALD prevention and treatment highlights the ongoing controversy about the association of IV lipid emulsions and PNALD. Various constituents of S-ILE have been linked to PNALD-high concentrations of phytosterols and ω-6 fatty acids, as well as insufficient concentrations of ω-3 fatty acids and vitamin E (α-tocopheral). [13] [14] [15] IV fish oil, which is dosed at 1 g/kg/d, has been associated with improved DB profiles and a possible decrease in transplantation rates and death from liver failure. 9, 10 Fish oil lacks phytosterols and contains a high concentration of eicosapentaenoic and docosahexaenoic acids (ω-3 fatty acids) and α-tocopherol, an antioxidant that prevents lipid peroxidation and oxidative injury. On the other hand, S-ILE, which is traditionally dosed at 3 g/kg/d, is replete with phytosterols and eicosapentaenoic and docosahexaenoic acids and contains higher concentrations of ω-6 fatty acids. Also, S-ILE contains Υ-tocopherol, which is not as biologically active as α-tocopheral. As a result, it remains controversial if the dose and/or composition of an IV fatty acid emulsion is responsible for the development and progression of PNALD. [7] [8] [9] [10] Normal human phytosterol intake is modest, and as a result, there is minimal phytosterol concentrations in the bloodstream. However, IV administration, especially to neonates, provides a large bolus that may overwhelm endogenous protective systems. 13, [26] [27] [28] [29] [30] Cell-based and animal work demonstrate that phytosterols decrease bile acid transport via the antagonism of the hepatic nuclear receptors farnesoid X and liver X (FXR and LXR). 13 In contrast, in a different animal model, the addition of α-tocopheral to S-ILE preserved liver function. Moreover, these animals had similar liver function compared with animals that received fish oil alone and fish oil plus phytosterols. 15 While these studies provide conflicting yet important information on the hepatic impact of different S-ILE constituents, there has yet to be a study examining the effect of 2 different doses of S-ILE on phytosterols and immunomodulatory and antioxidant biomarkers.
Limitations of our study include the unmasked design, small sample size, lower than excepted PNALD incidence, exclusion of neonates with necrotizing enterocolitis, missing data, and multiple comparisons. It would be challenging to effectively mask the S-ILE dose for this study as it is not routinely mixed in PN solutions at our institutions. However, glucose delivery rates were not different between the 2 arms despite the unmasked design (Table 4) . 7 Also, to control for S-ILE dose, patients were recruited shortly after birth. As a result, neonates with necrotizing enterocolitis, who are at high risk for PNALD, were not initially included in this study. 1 Last, because the prediction of which neonates will require long-term PN is sometimes difficult, 5 patients were excluded from the final analysis as they were weaned from PN by 14 days of age. 7, 8 
Conclusion
In this pilot study, a low dose of S-ILE was not associated with a change in cholestasis or short-term growth in neonates with GDs. However, a lower dose of S-ILE was associated with a slower DB increase over time. Considering the morbidity and mortality associated with pediatric PNALD, an appropriately powered study comparing low-dose S-ILE with the conventional higher dose of S-ILE is justified.
